Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab-Reply

JAMA Oncol. 2021 Feb 1;7(2):309-310. doi: 10.1001/jamaoncol.2020.6994.

Authors

Jonathan D Schoenfeld^{1

2}, Ravindra Uppaluri^{1

2}, Robert I Haddad^{1

2}

Affiliations

¹ Brigham and Women's Hospital, Boston, Massachusetts.
² Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

PMID: 33355594
DOI: 10.1001/jamaoncol.2020.6994

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Clinical Decision-Making
Humans
Ipilimumab / adverse effects
Neoadjuvant Therapy*
Nivolumab* / adverse effects

Substances

Ipilimumab
Nivolumab